US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

INVESCO BIOTECHNOLOGY & GENOME ETF

98.73

+1.431.47%

Post-market: 98.69-0.0465-0.05%19:30 EDT

Volume:7K

Turnover:644.33K

Market Cap:406.77M

PE:55.06

High:98.82

Open:97.68

Low:97.68

Close:97.30

52wk High:98.82

52wk Low:67.56

Shares:4.12M

Float Shares:4.12M

Volume Ratio:0.28

T/O Rate:0.16%

Dividend:1.55

Dividend Rate:1.57%

EPS(TTM):1.79

EPS(LYR):18.65

ROE:24.76%

ROA:0.08%

PB:1.64

PE(LYR):5.29

Loading ...

Overview Company News Filings

Grail announces FDA advisory committee meeting to review Galleri test PMA

Xenetic Biosciences Q2 Royalty Revenue Rises on Takeda Sublicense

Sino Biopharmaceutical Stock Climbs 3.3% in Hong Kong, Outperforms Competitors

Biogen completes acquisition of RayThera

Biogen Completes Acquisition of RayThera

Biogen Completes Acquisition of Raythera Inc.

THOMSON REUTERS

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Vortex Energy Study Confirms Major Salt Structure and New Target at Robinsons River

Biogen Extends Felzartamab Kidney Rejection Trial, Bolstering Long-Term Pipeline Story

Salesforce, UnitedHealth Share Losses Contribute to Dow's Nearly 150-Point Drop

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)

Royalty Pharma price target raised to $70 from $66 at Citi

Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million

Exelixis Q2 Revenue Misses Analyst Estimates, Lowers 2026 Outlook

Tenaya Therapeutics Q2 Net Loss Widens on Impairment Charge

Tenaya Net Loss Widens to $43.39 Million in Q2 FY26; R&D Expenses Slip to $16.6 Million

Vir Biotechnology Q2 Revenue Up, Beats Estimates on Astellas Payment

Biopharma Firm MannKind Q2 Posts Net Loss on Product Launch Expenses

Revolution Medicines Q2 FY26 Net Loss Widens to $644.4 Million; R&D Expenses Rise to $394.9 Million

Biopharma Firm Xencor's Q2 Revenue Beats on Royalty Revenue, Milestone Payments

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/PBE/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PBE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBE\",,,,,undefined,":{"symbol":"PBE","market":"US","secType":"STK","nameCN":"INVESCO BIOTECHNOLOGY & GENOME ETF","latestPrice":98.7315,"timestamp":1787688000000,"preClose":97.301,"halted":0,"volume":6544,"hourTrading":{"tag":"盘后","latestPrice":98.685,"preClose":98.7315,"latestTime":"19:30 EDT","volume":11,"amount":1086.1635,"timestamp":1787700601847,"change":-0.0465,"changeRate":-0.000471,"amplitude":0},"delay":0,"changeRate":0.014701801625882518,"floatShares":4120000,"shares":4120000,"eps":1.793292,"marketStatus":"Not Yet Opened","change":1.4305,"latestTime":"08-25 16:00:00 EDT","open":97.68,"high":98.82,"low":97.68,"amount":644330.0273600001,"amplitude":0.011716,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":1.793292,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":97.301,"sharesOutstanding":3180000,"nav":97.25464,"aum":401661663.2,"dividendRate":0.01567,"bidAskSpread":0.002967,"postHourTrading":{"tag":"盘后","latestPrice":98.685,"preClose":98.7315,"latestTime":"19:30 EDT","volume":11,"amount":1086.1635,"timestamp":1787700601847,"change":-0.0465,"changeRate":-0.000471,"amplitude":0},"volumeRatio":0.281845,"impliedVol":0.1495,"impliedVolPercentile":0.076},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBE\",,,,,undefined,":{"symbol":"PBE","floatShares":4120000,"roa":"0.08%","roe":"24.76%","lyrEps":18.654418,"volumeRatio":0.281845,"shares":4120000,"dividePrice":1.5471,"high":98.82,"amplitude":0.011716,"preClose":97.301,"low":97.68,"week52Low":67.56,"pbRate":"1.64","psRate":"236.96","week52High":98.82,"institutionHeld":0.2552,"latestPrice":98.7315,"eps":1.793292,"divideRate":0.01567,"volume":6544,"delay":0,"ttmEps":1.793292,"open":97.68,"prevYearClose":82.15,"prevWeekClose":97.59,"prevMonthClose":89.6108,"prevQuarterClose":89.6486,"fiveDayClose":95.28,"twentyDayClose":91.7375,"sixtyDayClose":83.8038},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBE\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"PBE","amount":0.81061,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"PBE","amount":0.08244,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"PBE","amount":0.41972,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"PBE","amount":0.23409,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"PBE","amount":0.13047,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBE\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-16","recordDate":"2016-09-20","paymentDate":"2016-09-30","value":0.02834,"currency":"USD"},{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-30","value":0.1208,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-31","value":0.05552,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-30","value":0.21532,"currency":"USD"},{"executeDate":"2018-09-24","recordDate":"2018-09-25","paymentDate":"2018-09-28","value":0.00207,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBE\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657642727","title":"Grail announces FDA advisory committee meeting to review Galleri test PMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2657642727","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657642727?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:10","pubTimestamp":1786115445,"startTime":"0","endTime":"0","summary":"GRAIL (GRAL) announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grail-announces-fda-advisory-committee-meeting-to-review-galleri-test-pma-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grail-announces-fda-advisory-committee-meeting-to-review-galleri-test-pma-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","LABU","XBIX","BK4585","BK4139","IBRN","SBIO","BBH","BBP","GRAL","BK4588","BK4129","PBE","PMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657645729","title":"Xenetic Biosciences Q2 Royalty Revenue Rises on Takeda Sublicense","url":"https://stock-news.laohu8.com/highlight/detail?id=2657645729","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657645729?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:44","pubTimestamp":1786106668,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences Q2 royalty revenue rises on Takeda sublicenseOverviewUS biopharma firm's Q2 royalty revenue rose 12% yr/yr, driven by Takeda sublicenseQ2 net loss widened to $0.9 mln from $0.7 mln","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL1N4440HO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XNCR","PBE","IHE","XBIO","AGEN","BK4139","BK4007","RPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657615971","title":"Sino Biopharmaceutical Stock Climbs 3.3% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2657615971","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657615971?lang=en_us&edition=fundamental","pubTime":"2026-08-07 16:30","pubTimestamp":1786091400,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. rallied 3.3% to 5.10 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.5% to 25668.03.This was the stock's second consecutive day of gains.Sino Biopharmaceutical Ltd. closed 44% below its 52-week high of HK$9.12, which the company reached Sept. 10.The stock outperformed some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 2.2% and Amgen Inc. remained unchanged.Trading volume totaled 88.6 million shares, compared to the 50-day average of 101.8 million shares.Data source: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","PJP","SG9999001440.SGD","LU0320765992.SGD","LU2242646821.SGD","BK4585","IE00BZ08YT58.USD","BIB","IE0002141913.USD","TBXU","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU1571399168.USD","IE00BJJMRZ35.SGD","BK4599","IE00BZ08YR35.GBP","IBB","BBH","HK0000165453.HKD","LU0868494617.USD","LU1023059063.AUD","LU1061106388.HKD","LU1983299246.USD","LU0889565916.HKD","LU2112291526.USD","LU2242652126.USD","LU0109394709.USD","BK4139","BK4581","LU0058720904.USD","LU0122379950.USD","BK1521","BK4588","BK1191","01177","BK4566","IE00BJT1NW94.SGD","BK4534","BK1589","LU2089984988.USD","BK1515","AMGN","BK4533","IBBQ","IE0009355771.USD","LU1057294990.SGD","LU0289739699.SGD","PBE","IE00B2B36J28.USD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657050661","title":"Biogen completes acquisition of RayThera","url":"https://stock-news.laohu8.com/highlight/detail?id=2657050661","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657050661?lang=en_us&edition=fundamental","pubTime":"2026-08-07 06:55","pubTimestamp":1786056934,"startTime":"0","endTime":"0","summary":"Biogen (BIIB) announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and devel...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biogen-completes-acquisition-of-raythera-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biogen-completes-acquisition-of-raythera-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","LU0234570918.USD","IEIH","BK4533","BK4585","AGNG","LU0889565916.HKD","SYNB","RSPH","PBE","IE00B894F039.SGD","BBP","FWD","LU0109394709.USD","IE00B19Z9P08.USD","JDOC","DARP","BK4532","BIIB","BMED","LNGR","IE00B19Z9Z06.USD","BK4588","XT","FHLC","LU0320765992.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657166970","title":"Biogen Completes Acquisition of RayThera","url":"https://stock-news.laohu8.com/highlight/detail?id=2657166970","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657166970?lang=en_us&edition=fundamental","pubTime":"2026-08-07 06:33","pubTimestamp":1786055631,"startTime":"0","endTime":"0","summary":"Biogen completes acquisition of RayTheraBiogen completed its acquisition of privately held RayThera, adding small-molecule immunology programs to its pipeline.The deal expands Biogen’s immunology port","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLjzXq7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B894F039.SGD","BK4112","BK4585","BK4139","SG9999014039.USD","SG9999014005.SGD","LU2095319765.USD","BIIB","BK4588","IE00BN0W2V16.EUR","LU0320765992.SGD","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","PBE","BK4532","LU0889565916.HKD","LU2210149790.SGD","LU0314104364.USD","IE00B19Z9Z06.USD","LU0109394709.USD","BK4533","IE00B19Z9P08.USD","BCDF","IE00B64PRP62.GBP","IE00BN0W2W23.USD","LU0234570918.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","BMED","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657699536","title":"Biogen Completes Acquisition of Raythera Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2657699536","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657699536?lang=en_us&edition=fundamental","pubTime":"2026-08-07 06:15","pubTimestamp":1786054500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA9DNYGT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BMED","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","BK4533","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","LU0234570918.USD","PBE","BK4588","BK4139","IE00B894F039.SGD","BIIB","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657085","title":"Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657085","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657085?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:11","pubTimestamp":1786047072,"startTime":"0","endTime":"0","summary":"Halozyme Q2 revenue jumps 48%, raises 2026 outlookOverviewU.S. biopharma firm's Q2 revenue rose 48% yr/yr, beating analyst expectationsAdjusted EPS for Q2 beat analyst expectationsCompany raised 2026 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","LU0053671581.USD","HELX","BK4139","LU1559883803.SGD","IHE","FFOX","BK4007","LGND","IE0009354923.USD","KYMR","PBE","LU0566484027.USD","RPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657567836","title":"Vortex Energy Study Confirms Major Salt Structure and New Target at Robinsons River","url":"https://stock-news.laohu8.com/highlight/detail?id=2657567836","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657567836?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:59","pubTimestamp":1786035577,"startTime":"0","endTime":"0","summary":"Vortex Energy Corp. ( ($TSE:VRTX) ) just unveiled an announcement. Vortex Energy Corp. reported final results from a technical study by Lonquist Fi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vortex-energy-study-confirms-major-salt-structure-and-new-target-at-robinsons-river?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vortex-energy-study-confirms-major-salt-structure-and-new-target-at-robinsons-river?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2362541513.USD","LU2456880835.USD","IE00BJT1NW94.SGD","IE00B19Z3B42.SGD","BK4139","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0289739699.SGD","LU2089984988.USD","SG9999013999.USD","LU1778281490.HKD","BIB","LU0417517546.SGD","LU2362541273.HKD","IE0002141913.USD","LU0061475181.USD","BK4588","LU1093756168.USD","LU1035775433.USD","IDNA","VRTX","BK4567","LU2462157665.USD","IBBQ","BBH","LU0256863811.USD","LU1430594728.SGD","SG9999001176.USD","LU2362540622.SGD","IE00B894F039.SGD","BK4532","TBXU","LU2468319806.SGD","LU0109394709.USD","IE00BZ9MQY76.HKD","LU2237438978.USD","LU2417539215.USD","IE00B4R5TH58.HKD","LU1674673428.USD","BK4585","PBE","SGXZ57979304.SGD","SG9999001176.SGD","LU0889565916.HKD","LU2236285917.USD","IBB","GNMX","LU1069344957.HKD","LU2324357040.USD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656902","title":"Biogen Extends Felzartamab Kidney Rejection Trial, Bolstering Long-Term Pipeline Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656902","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656902?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:41","pubTimestamp":1786034492,"startTime":"0","endTime":"0","summary":"Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Biogen extends study of kidney rejection drug felzartamab This long-term e...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biogen-extends-felzartamab-kidney-rejection-trial-bolstering-long-term-pipeline-story?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biogen-extends-felzartamab-kidney-rejection-trial-bolstering-long-term-pipeline-story?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU0889565916.HKD","IE00B19Z9Z06.USD","LU0234570918.USD","BIIB","BK4585","BK4532","BK4588","BMED","IE00B19Z9P08.USD","BK4139","LU0109394709.USD","PBE","BK4533","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657585496","title":"Salesforce, UnitedHealth Share Losses Contribute to Dow's Nearly 150-Point Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2657585496","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657585496?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:46","pubTimestamp":1786027560,"startTime":"0","endTime":"0","summary":"DJ Salesforce, UnitedHealth Share Losses Contribute To Dow's Nearly 150-Point DropThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Salesforce and UnitedHealth are seeing declines Thursday morning, dragging the Dow Jones Industrial Average into negative territory.Shares of Salesforce  and UnitedHealth  have contributed to the blue-chip gauge's intraday decline, as the Dow  was most recently trading 144 points lower .Salesforce's shares have fallen $6.53  while those of UnitedHealth have declined $6.27, or 1.5%, combining for a roughly 76-point drag on the Dow.Also contributing significantly to the decline are Boeing , Honeywell , and Amgen .A $1 move in any of the Dow's 30 components equates to a 5.94-point swing.Data source: Dow Jones Market Data, FactSet. Data compiled August 6, 2026.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0545039389.USD","SG9999017495.SGD","UNH","LU2326559502.SGD","LU0683600562.USD","LU1003077747.HKD","LU2491049909.HKD","LU0069063385.USD","LU0316494557.USD","LU2362540622.SGD","LU1732799900.SGD","TRUH","BK4154","BK4534","LU0648001328.SGD","LU0976567544.SGD","BIB","IE0002270589.USD","LU2324357040.USD","LU2286300806.USD","LU1316542783.SGD","IE00B894F039.SGD","LU2242649171.HKD","LU0058720904.USD","BOEG","LU2461242641.AUD","LU1934455194.USD","LU0211328371.USD","LU0353189680.USD","LU0557290698.USD","FHLC","SG9999018865.SGD","LU0689472784.USD","LU1804176565.USD","LU0310799852.SGD","SG9999014914.USD","PPA","LU0234570918.USD","IE00BKVL7J92.USD","LU1923623000.USD","LU0072461881.USD","LU0158827781.USD","LU0965509101.SGD","LU2244417387.USD","BK4023","BK4579","LU2279689827.SGD","LU1074936037.SGD","LU0109391861.USD","LU0354030438.USD","LU2242652126.USD","IE00BQXX3D17.EUR","PBE","BK4206","BK4527","IBB","IE00B2B36J28.USD","BK4599","LU2265009873.SGD","IE00B7KXQ091.USD","LU0052756011.USD","LU1046421795.USD","LU0980610538.SGD","BBH","LU0053666078.USD","LU1803068979.SGD","LU0048573561.USD","LU2491050154.USD","LU2999663052.SGD","LU2954938101.SGD","LU0496365809.HKD","LU0251131958.USD","LU1066051225.USD","LU0143551892.USD","LU0648000940.SGD","BK4607","TBXU","LU1037948541.HKD","LU1791710582.SGD","IYH","IE0004445015.USD","LU0795875169.SGD","LU1551013342.USD","LU1023059063.AUD","LU2756315318.SGD","LU0511384066.AUD","UNHW","LU0029864427.USD","IE00BFSS7M15.SGD","HRTS","LU1066051498.USD","LU0128525689.USD","LU0342679015.USD","LU0097036916.USD","MHIP","LU0128525929.USD","LU0109394709.USD","IE00BN29S564.USD","LU0289739343.SGD","LU1854103824.USD","LU0320765992.SGD","LU0820561818.USD","LU1674673691.USD","LU1934455277.USD","BK4602","SG9999014898.SGD","LU0868494617.USD","LU1934455863.HKD","LU2125154935.USD","SG9999002224.SGD","IE00BFXG1179.USD","LU0157215616.USD","IE00B775H168.HKD","LU1267930227.SGD","BK4598","SG9999018857.SGD","IE00BSNM7G36.USD","LU0077335932.USD","LU1064131342.USD","LU0094547139.USD","LU1670628061.USD","LU0314104364.USD","LU1989771016.USD","LU0472753341.HKD","LU2264538146.SGD","NATO","LU2236285917.USD","BK4564","LU1084165304.USD","LU0965508806.USD","LU1823568750.SGD","LU0251132253.USD","LU0868494708.USD","IE00B19Z9P08.USD","IE00B4JS1V06.HKD","LU1035773651.USD","AMGN","LU0107464264.USD","LU0528227936.USD","IE00B19Z3581.USD","LU1914381329.SGD","IE00B19Z8W00.USD","BK4561","LU0320765059.SGD","LU0738911758.USD","BK4538","IE00BJJMRY28.SGD","BK4581","LU0106261372.USD","LU0965509283.SGD","LU0310800379.SGD","LU2023251221.USD","LU0130103400.USD","IE00BFSS8Q28.SGD","LU1983299246.USD","LU1323610961.USD","LU0149725797.USD","IDEF","BK4566","LU1496350171.SGD","LU1988902786.USD","IE00B3T34201.USD","LU1429558221.USD","JDOC","IE0004445239.USD","IE00B19Z3B42.SGD","SG9999001176.SGD","LU2211815571.USD","LU0354030511.USD","LU0689626769.HKD","LU1119994496.HKD","LU0203347892.USD","IE0002141913.USD","LU1718418525.SGD","LU1496350502.SGD","LU2089984988.USD","LU1670627923.USD","LU0109392836.USD","LU0942090050.USD","IBBQ","LU0787776722.HKD","LU1435385759.SGD","IE00BQXX3C00.GBP","IE0034235188.USD","LU0187121727.USD","LU1548497426.USD","BK4567","LU0289739699.SGD","LU0162691827.USD","LU2112291526.USD","LU0211327993.USD","LU1989764664.SGD","BA","LU0477156797.USD","IE000M9KFDE8.USD","LU0965509010.AUD","LU0820562030.AUD","LU0708994859.HKD","IE00BZ9MQY76.HKD","LU1069347547.HKD","BK4548","LU0345770308.USD","LU1057294990.SGD","LU2271345857.HKD","LU0943347566.SGD","LU0792757196.USD","LU1571399168.USD","IHF","CRMG","LU1291159041.SGD","LU1066053197.SGD","BK4588","BK4139","LU1506573853.SGD","LU2360032135.SGD","LU0672654240.SGD","LU0719512351.SGD","LU0642271901.SGD","04332","IE00BJJMRZ35.SGD","LU2028103732.USD","LU1061106388.HKD","LU0079474960.USD","LU2111349929.HKD","BK4585","GDOC","LU0203345920.USD","SG9999014880.SGD","SGXZ57979304.SGD","FOWF","IE00BFTCPJ56.SGD","BK4543","IE00BJJMRX11.SGD","SG9999001176.USD","LU0114720955.EUR","LU1267930573.SGD","LU1267930490.SGD","BK4613","BK4551","LU0661504455.SGD","LU0251142724.SGD","LU2756315664.SGD","LU0477156953.USD","LU0708995401.HKD","HON","LU1235294995.USD","SGXZ51526630.SGD","LU1201861249.SGD","LU0211326755.USD","LU0889565833.HKD","IE0009355771.USD","LU0742534661.SGD","UNHG","SG9999001440.SGD","LU2133065610.SGD","LU0823416689.USD","LU2552382058.USD","LU0353189763.USD","IE0005OL40V9.USD","LU0081259029.USD","ITA","IE00B19Z9505.USD","IE00B4R5TH58.HKD","IE00B19Z9Z06.USD","VHT","LU0266013472.USD","IE00B1BXHZ80.USD","LU2087625088.SGD","LU0889565916.HKD","LU1951198990.SGD","LU2361044865.SGD","CRM","LU0456855351.SGD","IE00B1XK9C88.USD","LU1261432733.SGD","BK4533","LU2361044949.HKD","LU1989764748.USD","LU0267386448.USD","LU0310800965.SGD","SG9999002232.USD","LU1267930730.SGD","BK4528","BK4505","LU1732800096.USD","LU0130518102.USD","RXL","LU2247934214.USD","SGXZ99366536.SGD","LU2552382132.HKD","PJP","LU0820561909.HKD","BK4516","SGXZ31699556.SGD","LU0130102774.USD","LU0158827948.USD","LU0127658192.USD","LU0198837287.USD","LU1720051017.SGD","LU2458330243.SGD","LU2089283258.USD","LU0949170772.SGD","LU1551013425.SGD","LU1201861165.SGD","UNHU","LU1066051811.HKD","LU2347655156.SGD","LU2242646821.SGD","LU0553294199.USD","LU0289961442.SGD","IE00BZ1G4Q59.USD","LU0256863811.USD","TMED","LU2361045086.USD","LU1854104046.USD","BK4532","IE00B7SZLL34.SGD","LU1366333091.USD","LU1674673428.USD","LU2357305700.SGD","LU2362541513.USD","LU1791710400.SGD","LU0345770993.USD","LU0124676726.USD","BK4535","IE00BKPKM429.USD","BOEU","LU0211326839.USD","IXJ","MISL","IE00B19Z8X17.USD","LU0861579265.USD","SG9999014906.USD","LU0057025933.USD","IE00BWXC8680.SGD","LU0006306889.USD","IE00BJTD4V19.USD","IE00BJT1NW94.SGD","BK4550","IE00BJTD4N35.SGD","LU2362541273.HKD","LU0417517546.SGD","LU1951200564.SGD","LU2491050071.SGD","LU1778281490.HKD","LU0082616367.USD","LU1814569148.SGD","BK4608","LU1267930813.SGD","LU0432979614.USD","LU0130517989.USD","SGXZ81514606.USD","LU2458330169.SGD","LU2468319806.SGD","XLV","LU0122379950.USD","LU0889566641.SGD","IE00BQXX3F31.USD","LU0238689110.USD","BK4187","BOED","LU1037948897.HKD","LU0234572021.USD","LU2125154778.USD","LU0048584097.USD","SG9999013999.USD","LU2552382215.SGD","LU0912757837.SGD","LU1153585028.USD","LU1720051108.HKD","LU0882574055.USD","LU2089284900.SGD","LU0011850046.USD","LU0795875086.SGD","LU2462591277.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639266","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639266","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639266?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:10","pubTimestamp":1786018244,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-revolution-medicines-rvmd-royalty-pharma-rprx-and-urogen-pharma-urgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-revolution-medicines-rvmd-royalty-pharma-rprx-and-urogen-pharma-urgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","IE00B4R5TH58.HKD","IDNA","IE00BJJMRZ35.SGD","XLV","LU0320765992.SGD","HCSG","LU0128526141.USD","IE00B2B36J28.USD","PBE","LABU","IE00BJT1NW94.SGD","XBI","BK4585","IHE","IE0009354923.USD","BK4137","BK4007","LU0889565916.HKD","BK4581","CANC","RVMD","BBH","RPRX","IE0009355771.USD","PTH","IE00BFTCPJ56.SGD","LU0029874061.USD","URGN","LU0109394709.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657368722","title":"Royalty Pharma price target raised to $70 from $66 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2657368722","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657368722?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:41","pubTimestamp":1786012903,"startTime":"0","endTime":"0","summary":"Citi raised the firm’s price target on Royalty Pharma (RPRX) to $70 from $66 and keeps a Buy rating on the shares. The firm views the company’s Q2 ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/royalty-pharma-price-target-raised-to-70-from-66-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/royalty-pharma-price-target-raised-to-70-from-66-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","IHE","RPRX","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657682336","title":"Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657682336","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657682336?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:11","pubTimestamp":1786011111,"startTime":"0","endTime":"0","summary":"Generate Biomedicines Q2 FY26 net loss widens to $67.26 million; revenue drops to $6.31 millionGenerate Biomedicines posted a GAAP net loss of $67.26 million for the quarter ended June 30, 2026, widen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL8LfD7q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","IBB","LU1057294990.SGD","LU2242646821.SGD","TBXU","LU1571399168.USD","BK4534","SG9999001440.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0889565916.HKD","IE0002141913.USD","LU2242652126.USD","BK4599","BIB","LU0868494617.USD","IE00B4R5TH58.HKD","IE0009355771.USD","LU2089984988.USD","IE00BFTCPJ56.SGD","BBH","BK4566","BK4581","AMGN","LU1983299246.USD","PJP","PBE","BK4585","LU2112291526.USD","LU0058720904.USD","IBBQ","BK4533","LU1061106388.HKD","BK4139","LU1023059063.AUD","BK4588","LU0109394709.USD","LU0122379950.USD","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657357543","title":"Exelixis Q2 Revenue Misses Analyst Estimates, Lowers 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657357543","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657357543?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:53","pubTimestamp":1785963209,"startTime":"0","endTime":"0","summary":"Exelixis Q2 revenue misses analyst estimates, lowers 2026 outlookOverviewU.S. oncology firm's Q2 revenue rose yr/yr but missed analyst expectationsAdjusted net income for Q2 beat analyst estimatesComp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421EH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU2468319806.SGD","LU0122379950.USD","LU2089984988.USD","LU2242652126.USD","IE00B4R5TH58.HKD","LU2242646821.SGD","URGN","LU1571399168.USD","BK4534","IE0002141913.USD","BK4581","IE0009355771.USD","BK4588","IE00BJJMRZ35.SGD","LU1057294990.SGD","PBE","PJP","TBXU","BIB","LU0289739699.SGD","LU1061106388.HKD","LU0109394709.USD","BK4139","BK4585","EXEL","LU1023059063.AUD","LU0868494617.USD","IBB","AMGN","LU0058720904.USD","IBBQ","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4566","BK4533","LU2112291526.USD","BK4599","IE00BJT1NW94.SGD","LU0320765992.SGD","SG9999001440.SGD","BBH","LU1983299246.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657575666","title":"Tenaya Therapeutics Q2 Net Loss Widens on Impairment Charge","url":"https://stock-news.laohu8.com/highlight/detail?id=2657575666","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657575666?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:46","pubTimestamp":1785962781,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Q2 net loss widens on impairment chargeOverviewUS heart disease therapy developer's Q2 net loss widened, driven by impairment chargeCompany received $10 mln upfront payment from Al","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421DL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ALNY","LU0320765992.SGD","LU0114720955.EUR","LU0889565916.HKD","BK4585","BK4588","LU0882574055.USD","BK4548","IMRX","LU0109394709.USD","BK4139","TNYA","BK4563","PBE","TRDA","GNMX","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657755525","title":"Tenaya Net Loss Widens to $43.39 Million in Q2 FY26; R&D Expenses Slip to $16.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657755525","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657755525?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:44","pubTimestamp":1785962666,"startTime":"0","endTime":"0","summary":"Tenaya net loss widens to $43.39 million in Q2 FY26; R&D expenses slip to $16.6 millionTenaya Therapeutics posted a Q2 net loss of USD 43.4 million, or USD 0.20 a share, widening from USD 23.3 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL8RShts:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0109394709.USD","PBE","IE00BN0W2W23.USD","BK4585","LU2210150020.SGD","BK4588","LU0320765992.SGD","GNMX","LU0882574055.USD","LU2210149790.SGD","BK4112","BK4539","LU0889565916.HKD","ALNY","BCDF","BK4548","NDAQ","BK4139","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","TNYA","LU0314104364.USD","LU2095319765.USD","SG9999014013.SGD","LU0114720955.EUR","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657578623","title":"Vir Biotechnology Q2 Revenue Up, Beats Estimates on Astellas Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2657578623","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657578623?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:20","pubTimestamp":1785961240,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Q2 revenue up, beats estimates on Astellas paymentOverviewU.S. biopharma's Q2 revenue rose sharply, beating analyst expectationsQ2 net income was $80.1 mln, reversing a net loss last","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421BR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","KYMR","LU1585245621.USD","LU1061106388.HKD","LU1934455863.HKD","LU0114720955.EUR","IBB","IE00B19Z3B42.SGD","LU1066051498.USD","SG9999015945.SGD","BK4550","LU0889565916.HKD","PJP","IE00B4R5TH58.HKD","IE00B3T34201.USD","BK4535","BK4599","LU0823416689.USD","LU0861579265.USD","IE0002270589.USD","LU0965509101.SGD","LU1430594728.SGD","LU2324357040.USD","PBE","TMED","IE00BJJMRZ35.SGD","GILD","IE00BJT1NW94.SGD","BIB","LU0882574055.USD","SG9999015978.USD","BMED","LU0234570918.USD","LU0289739699.SGD","LU1674673691.USD","LU1983299246.USD","LU1057294990.SGD","IBBQ","BBH","LU1839511570.USD","LU2087621335.USD","VIR","AMGN","LU0868494617.USD","LU1571399168.USD","IE00BSNM7G36.USD","TBXU","MEDI","BK4568","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657578367","title":"Biopharma Firm MannKind Q2 Posts Net Loss on Product Launch Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657578367","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657578367?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:18","pubTimestamp":1785961095,"startTime":"0","endTime":"0","summary":"Biopharma firm MannKind Q2 posts net loss on product launch expensesOverviewUS biopharma firm's Q2 revenue rose 43% yr/yr, driven by Furoscix and higher royaltiesCompany posted a Q2 net loss as expens","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421BD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RPRX","LU1571399168.USD","BK4007","LU1699723380.USD","BK4532","MNKD","UTHR","BK4139","PBE","BK4584","IHE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657057882","title":"Revolution Medicines Q2 FY26 Net Loss Widens to $644.4 Million; R&D Expenses Rise to $394.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657057882","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657057882?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:17","pubTimestamp":1785961029,"startTime":"0","endTime":"0","summary":"Revolution Medicines Q2 FY26 net loss widens to $644.4 million; R&D expenses rise to $394.9 millionRevolution Medicines posted a GAAP net loss of $644.4 million for Q2 2026, widening from a $247.8 mil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL46m7gf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","IE00BKPKM429.USD","SG9999014039.USD","IE00B4R5TH58.HKD","LU2095319765.USD","IE00BN0W2W23.USD","IDNA","IE00BJJMRZ35.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","LU0320765992.SGD","IE00BGHQF748.EUR","IE00B2B36J28.USD","IE00B3QW5Z07.USD","PBE","IE00BJT1NW94.SGD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4585","LU2210150020.SGD","SG9999014021.USD","IE0009354923.USD","IHE","LU0889565916.HKD","BK4007","SG9999014013.SGD","CANC","RVMD","NDAQ","BBH","BCDF","IE0009355771.USD","IE00BN0W2T93.GBP","RPRX","PTH","IE00BFTCPJ56.SGD","BK4112","LU2210149790.SGD","LU0109394709.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657520170","title":"Biopharma Firm Xencor's Q2 Revenue Beats on Royalty Revenue, Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2657520170","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657520170?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:13","pubTimestamp":1785960830,"startTime":"0","endTime":"0","summary":"Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone paymentsOverviewUS biopharma firm's Q2 revenue rose, beating analyst expectationsCompany posted narrower net loss of $21.7 mln, o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421AV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4007","BK4139","PBE","KYMR","IHE","RPRX","IMRX","ZBIO","BK4539","XNCR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}